Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLY-HF: Polypill for HFrEF in Underserved Populations
NCT04633005Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metoprolol, empagliflozin, spironolactone in heart failure with reduced ejection fraction (HFrEF), sponsored by UT Southwestern Medical Center. Started Nov 2021; status: completed.
02
Drugs
metoprololempagliflozinspironolactone
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04633005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633005.